一分钟看懂
这是一项关于癌症的I 期 / II 期研究，登记的药物或干预包括TST001；Oxaliplatin；Capecitabine；Paclitaxel；Gemcitabine；Cisplatin；Nivolumab，当前状态为研究进行中，已停止招募。登记地点显示中国蚌埠、北京、重庆、福州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
TST001；Oxaliplatin；Capecitabine；Paclitaxel；Gemcitabine；Cisplatin；Nivolumab · I 期 / II 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- The First Affiliated Hospital of Bengbu Medical College · 蚌埠
- Beijing Cancer Hospital · 北京
- Beijing Friendship Hospital, Capital Medical University · 北京
- Peking Union Medical College Hospital · 北京
- Peking University International Hospital · 北京
- The First Affiliated Hospital of Chongqing Medical University · 重庆
- Fujian Cancer Hospital · 福州
- Fujian Medical University Union Hospital · 福州
- The First Affiliated Hospital of Xiamen University · 厦门
- The Sixth Affiliated Hospital of Sun Yat-sen University · 广州
- The People's Hospital of Guangxi Zhuang Autonomous Region · 广西壮族自治区
- Hainan Provincial People's Hospital · 海口
- The First Affiliated Hospital of Zhengzhou University · 郑州
- Harbin Medical University Cancer Hospital · 哈尔滨
- Henan Cancer Hospital · 郑州
- Hubei Cancer Hospital · 武汉
- Zhongnan Hospital of Wuhan University · 武汉
- Hunan Cancer Hospital · 长沙
- Xiangya Hospital, Central South University · 长沙
- Suzhou Municipal Hospital · 苏州
- The Second Affiliated Hospital of Soochow University · 苏州
- Xuzhou Central Hospital · 徐州
- The Second Affiliated Hospital of Nanchang University · 南昌
- Jilin Cancer Hospital · 长春
- The First Hospital of Jilin University · 长春
- The First Affiliated Hospital of Jinzhou Medical University · Jinzhou
- Liaoning Cancer Hospital & Institute · 沈阳
- The First Hospital of China Medical University · 沈阳
- Jinan Central Hospital · 济南
- Linyi Cancer Hospital · 临沂
- The Affiliated Hospital of Qingdao University · 青岛
- Fudan University Shanghai Cance Center · 上海
- Zhongshan Hospital Fudan University · 上海
- Sichuan Cancer Hospital · 成都
- West China Hospital, Sichuan University · 成都
- Tianjin Medical University Cancer Institute & Hospital · 天津
- Tianjin Medical University General Hospital · 天津
- First Affiliated Hospital of Zhejiang University · 杭州
- The Second Affiliated Hospital of Zhejiang University School of Medicine · 杭州
- Zhejiang Cancer Hospital · 杭州
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- The subjects who meet all inclusion criteria can be enrolled into the trial:
- 1. Sign the Informed Consent Form (ICF) voluntarily, understand the study and be willing and able to comply with all study procedures;
- 2. Male or female ≥ 18 years at signing the ICF;
- 3. Suffer from histologically confirmed locally unresectable advanced or metastatic solid tumors and meet the criteria of corresponding cohort as follows:
- Mono-therapy dose escalation and expansion phase:
- 1. Mono-therapy dose escalation study: The subjects who have no option of or are intolerable to SOC.
- 2. Mono-therapy dose expansion study: The subjects with positive CDLN18.2 expression in tumor tissue (defined as CLDN18.2 membranous staining ≥1+ in ≥10% of tumor cells by immunohistochemistry (IHC) in the central laboratory) confirmed by the central laboratory at enrollment. The dose expansion study may include the following 3 cohorts:
- Cohort A: Subjects with G/GEJ adenocarcinoma who have no option of or are intolerable to SOC; Cohort B: Subjects with ductal adenocarcinoma of pancreas who have no option of or are intolerable to SOC; Cohort E: Subjects with other locally advanced or metastatic solid tumors excluding G/GEJ adenocarcinoma (limited to biliary tract neoplasms, lung adenocarcinoma or colorectal cancer) who have no option of or are intolerable to SOC; Part II
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT04495296；登记信息更新于 2026-09-29；本站同步于 2026-10-08。